27 October 2017 - Kyowa Hakko Kirin today announces that its marketing authorisation application for mogamulizumab, for the treatment of cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy, has been validated by the EMA and is now under review.

This application is based on the data from the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) study, the largest global randomised clinical trial of systemic therapy in CTCL.

Read Kyowa Hakko Kirin press release